Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting advancement toward IND submissionTEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced safety data supporting the continued development of OcuRing™-K dr ...